Tissium’s $68M Raise and the Power of a Narrow De Novo

Somewhere in Tissium’s regulatory file is a sentence most founders would read as a limitation. The company’s first commercial product, Coaptium Connect, is cleared by the FDA to do one thing: repair a peripheral nerve, without sutures, when the gap is a centimeter or less. Not nerves in general. Not the whole platform of light-activated polymers that might one day seal a hernia or a blood vessel. One injury, one centimeter. On June 25, MedTech Dive reported that Tissium had pulled together 60 million euros, about 68 million dollars, to carry that narrow product into the U.S. operating room. The narrow scope is not the weakness in this story. It is why the money showed up.

The indication is the product

Coaptium Connect pairs a bioresorbable, light-activated surgical polymer with a 3D-printed chamber, applied with a device Tissium calls its Light. The FDA granted it a De Novo classification, the pathway for a device novel enough that no predicate exists to match it against. The broader platform reaches toward hernia repair, in the clinic under the name Eclipsium, and cardiovascular sealing, still in the pipeline, and the company has raised roughly 200 million euros over its life. But the FDA did not clear a platform. It cleared one indication with a boundary you can measure with a ruler. That precision is the regulatory strategy, not a footnote to it.

What a De Novo actually buys you

At Galen, we did not choose the De Novo. The FDA routed us to it, and most founders miss that signal when it lands. We had turned in a pre-submission, which a lot of people misread as a chance to ask the agency a list of questions. It is not. It is a strategy presentation. You state your plan, and they nod or they do not. The agency came back and told us our predicates were not appropriate for a 510(k) with the device as we had described it, and that we might be better suited to a De Novo. We took the hint.

What surprised me is that the De Novo is an advantage. The FDA suggesting it means the agency already sees you as moderate risk, because a genuinely high-risk device would be in a PMA by then. You also get to define the safety story yourself, instead of inferring a competitor’s test plan telepathically from a clearance you are not allowed to read. The best part came at the end. When you win a De Novo, the FDA has to write a new regulation for your device, because none exists, and they asked us what it should say. We sent a paragraph. They asked for it in Word. A day or two later the regulation describing our device read word for word what we had written. We became the predicate. Tissium just did the same thing for sutureless nerve repair, and the next company that wants to do this has to prove it is substantially equivalent to Tissium.

The capital followed the cleared product, not the platform

Look at how the money is built. About 30 million euros is a Series D2 that closed at the end of 2025, and up to another 30 million comes from the European Investment Bank in three 10-million tranches, each released against commercial, clinical, and financing milestones. The institutional half of the raise is not a bet on the platform vision. It is metered against the commercialization of one cleared product. The investors are underwriting what the FDA has already de-risked. If you are a founder holding a platform technology, a biomaterial or a novel mechanism that could plausibly do ten things, that structure is worth studying. Pick the one indication you can define tightly enough to clear, clear it, and let the rest of the platform compound off a product that exists rather than a deck that promises five.

Dave Saunders is the founder of Base Reality Group and a Fractional CPO for hard-tech founders. He was a founder and operator at Galen Robotics, where the surgical-robotics platform earned FDA De Novo authorization in 2023, and he managed a 35-patent portfolio licensed from Johns Hopkins. He wrote Founders Who Finish and publishes The Build. More about Dave →